GeneDx Holdings Corp.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Katherine A. Stueland
- Full Time Employees
- 1,300
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- North Tower Stamford CT United States of America 06902
- IPO Date
- Nov 4, 2020
- CIK
- 0001818331
- Website
- genedx.com
- Similar Companies
- Business
- GeneDx Holdings Corp. operates as a genetic testing and genomic information company specializing in clinical genetic testing services and genomic diagnostics. It offers a comprehensive range of products and services including hereditary disease testing, rare and ultra-rare disease diagnostics, prenatal genetic testing, oncology-related genetic analysis, carrier screening, pharmacogenomics, and whole exome and genome sequencing assays. The company addresses clinical needs through specialized genetic tests, interpretation services, and advanced genomic data analysis primarily for healthcare providers, researchers, and pharmaceutical companies. Headquartered in Gaithersburg, Maryland, and founded in 2000, GeneDx serves a broad geographic market including the United States and international locations. Recent major company developments include strategic expansions in partnerships and service offerings to enhance precision medicine capabilities, with a focus on expanding its testing panels and integrating advanced bioinformatics tools. GeneDx has made significant strides in developing new genetic tests tailored for rare diseases and oncology, reflecting a strategic emphasis on personalized medicine and broader clinical application. These advancements are alongside ongoing investments in research and development to support novel diagnostic solutions. GeneDx is positioned within the molecular diagnostics and genomics industry, targeting clinicians, hospitals, research institutions, and biopharmaceutical firms. It is part of a growing sector driven by advances in genetic sequencing technologies and the increasing demand for personalized healthcare solutions. This detailed profile encapsulates GeneDx’s core business activities, product portfolio, recent strategic initiatives, industry context, and market focus, reflecting its role as a leading provider of genomic testing services.
Company News
GeneDx (NASDAQ:WGS) Stock Falls 5.5% – Here’s What Happened
Analyzing GeneDx (NASDAQ:WGS) and LifeMD (NASDAQ:LFMD)
Comparing GeneDx (NASDAQ:WGS) & Brookdale Senior Living (NYSE:BKD)
GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026
GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026
GeneDx Holdings Corp (WGS) Shares Surge 4.3% -- What GF Score of 67 Tells Investors
GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care
Kevin Feeley Sells 3,728 Shares of GeneDx (NASDAQ:WGS) Stock
Tempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare Innovation
GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C
3 Promising Genomics Stocks in the Spotlight in 2026
GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree
GeneDx Holdings Corp (WGS) Shares Surge 3.3% -- What GF Score of 65 Tells Investors
Short Sellers Are All-In on These 10 Stocks — Squeeze Watch List Inside
GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children's
GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children's
Can GENEDX HOLDINGS (WGS) Run Higher on Rising Earnings Estimates?
GeneDx: Why I Think The Worst Is Behind The Business
Is GeneDx Holdings Corp (WGS) Overvalued After 5.1% Rally? GF Value Says Overvalued
GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy